- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01464320
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single-Dose of ABT-614 and the Effect of ABT-614 on Glomerular Filtration Rate in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Albuminuria
Study Overview
Status
Intervention / Treatment
Detailed Description
This Phase 1b, single-site, double-blind, randomized, placebo-controlled study will be conducted in three Periods; Baseline, Dosing and Outpatient. Eligible adult male and female subjects with type 2 diabetes and CKD (chronic kidney disease) with albuminuria will be selected to participate.
Eighteen subjects will be selected to participate in the Baseline Period to ensure that 16 subjects are enrolled in the Dosing Period. Subjects who are eligible from Screening will be confined to the study site beginning on Day -2 (the day before the Baseline Period infusion). On Day -1, subjects will be administered an iothalamate infusion to measure baseline GFR (glomerular filtration rate). Subjects who continue to be eligible on Day 1 will be randomized in a 1:1 ratio to receive either a 10 mg dose of ABT-614 or matching placebo daily, for 15 days.
On Day 15 subjects will be administered a second iothalamate infusion. Plasma and urine samples for ABT-614 and iothalamate will be collected. Subjects will be released from confinement on Day 20 after the completion of all study procedures including the 120-hour blood sample collection. Thereafter, subjects will return for outpatient visits on Days 25 and 30 as well as 30 days after the last dose of study drug. A ± 2 day window will be permitted on the 30-day Follow-up Visit to accommodate subject scheduling.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Site Reference ID/Investigator# 63442
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male or female aged between 19 and 70 years, inclusive, at time of consent.
- Type 2 diabetes receiving at least one anti-diabetic medication for at least one year at the time of Screening.
- Hemoglobin A1c < 12% at the time of Screening.
- Estimated glomerular filtration rate ≥ 30 mL/min calculated by the Cockcroft-Gault Formula at the time of Screening.
- Urinary albumin to creatinine ratio 100 to 5000 mg/g creatinine at the time of Screening.
Exclusion Criteria
- History of unusual or allergic reaction to iodine, to products containing iodine (for example., iodine containing foods) or to other radio-opaque agents.
- Subject history of epileptic seizures or convulsions.
- Clinically significant cardiac disease or family history of long-QT syndrome and/or subject and/or family history of unexplained, sudden cardiac death. History of myocardial infarction or coronary artery bypass graft is not exclusionary if occurrence is ≥ 12 months prior to the administration of study drug and the subject does not have conduction abnormality and has been stable without intervention, symptoms of ischemia or an increase in cardiovascular medications. Electrocardiography (ECG) should be compared with historical to ensure no new clinically significant changes have occurred.
- History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, potential hydrogen (pH) or absorption.
- Clinically significant respiratory (except mild asthma), gastrointestinal, hematologic, neurologic, thyroid or any uncontrolled medical illness or psychiatric disease or disorder.
- Screening ECG with clinically significant abnormalities and/or confirmed Screening QTcF prolongation more than 430 milliseconds for males and 450 milliseconds for females or ECG with second or third degree atrioventricular block.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Comparator
|
Placebo
|
Experimental: ABT-614
|
Active
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in drug concentration
Time Frame: Day -1 (Baseline) and up to Day 15
|
Blood and urine tests
|
Day -1 (Baseline) and up to Day 15
|
Change in glomerular filtration rate
Time Frame: Day -1 (Baseline) and up to Day 15
|
Blood and urine tests
|
Day -1 (Baseline) and up to Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urinary albumin excretion
Time Frame: Day -1 (Baseline) and up to Day 15
|
Urine tests
|
Day -1 (Baseline) and up to Day 15
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Dennis Andress, MD, Renal Global Project Team, Abbott Laboratories
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M13-107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
-
BayerCompletedChronic Kidney Disease in Type 2 DiabetesCanada
-
The Royal Wolverhampton Hospitals NHS TrustCompletedEnd Stage Renal Disease (ESRD) | Chronic Kidney Disease (CKD) | Acute Kidney Injury (AKI) | Estimated Glomerular Filtration Rate (eGFR) | Neutrophil Gelatinase-associated Lipocalin (NGAL) | Serum Creatinine (SCr) | Urine Creatinine (UCr) | Urine Albumin (UAlb)United Kingdom
-
Hoffmann-La RocheWithdrawnDiabetes Mellitus Type 2, Kidney Disease, Chronic
-
Lexicon PharmaceuticalsSanofiCompletedType 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
-
Lexicon PharmaceuticalsSanofiCompletedType 2 Diabetes Mellitus | Chronic Kidney Disease Stage 4United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
-
Rennes University HospitalCompletedType 2 Diabetes, Chronic Kidney DiseaseFrance
-
Hospital Universitario Dr. Jose E. GonzalezCompletedChronic Kidney Disease Due to Hypertension | Chronic Kidney Disease Due to Type 2 Diabetes MellitusMexico
-
Peking University Third HospitalNot yet recruitingType 2 Diabetes | Pregnancy in DiabeticChina
-
Mount Sinai Hospital, CanadaUniversity Health Network, Toronto; Canadian Institutes of Health Research... and other collaboratorsCompleted
-
Mount Sinai Hospital, CanadaCanadian Institutes of Health Research (CIHR); Sunnybrook Research InstituteCompleted
Clinical Trials on Placebo Comparator
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminated
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCTerminatedType 2 Diabetes
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Esther MeijerUnknownPolycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney | ADPKDNetherlands